Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10668140 | 0.89 | OPRK1 (0.49) | OPRK1MAPK1KMT2ATARBP2NPSR1 | |
| SCHEMBL16663609 | 0.84 | KDM4E (0.44) | OPRK1MAPK1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL17362538 | 0.84 | TARBP2 (0.42) | OPRK1MAPK1KMT2AKDM4ETARBP2 | |
| SCHEMBL17362509 | 0.84 | HSD17B10 (0.49) | OPRK1MAPK1KMT2AKDM4EL3MBTL1 | |
| SCHEMBL289542 | 0.83 | OPRK1 (0.44) | OPRK1NPSR1 | |
| SCHEMBL25765775 | 0.83 | KDM4E (0.46) | MAPK1KMT2AKDM4EL3MBTL1TARBP2 | |
| SCHEMBL15351111 | 0.81 | CYP2C19 (0.54) | MAPK1KMT2AKDM4EL3MBTL1CYP2C9 | |
| SCHEMBL24212612 | 0.80 | HSD17B10 (0.46) | OPRK1MAPK1KMT2AKDM4ETARBP2 | |
| SCHEMBL29362361 | 0.80 | TARBP2 (0.39) | OPRK1MAPK1KMT2AKDM4ETARBP2 | |
| SCHEMBL24212384 | 0.80 | TARBP2 (0.39) | OPRK1MAPK1KMT2AKDM4ETARBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E THERAPEUTICS, INC. | 2025-06-26 | — | — | US | disclosed |
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E THERAPEUTICS, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4380566-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | 4E Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118076354-A | Methods of treating migraine with MNK inhibitors | 4E治疗公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4363419-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | 4E Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117980305-A | Spirocyclic pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof | 4E治疗公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-3521289-B1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| CN-116194112-A | Pyridine-1, 5-diones exhibiting MNK inhibition and methods of use thereof | 4E治疗公司 | 2023-05-30 | — | — | CN | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200481-A1 | MNK INHIBITORS AND METHODS RELATED THERETO | EFFECTOR THERAPEUTICS, INC. (US) | 2015-12-30 | — | — | WO | disclosed |
| US-20140256715-A1 | Novel Oxazine Derivatives and their use in the Treatment of Disease | NOVARTIS AG (CH) | 2014-09-11 | — | — | US | disclosed |
| EP-2766358-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013054291-A1 | NOVEL OXAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2013-04-18 | — | — | WO | disclosed |
| EP-1625119-B1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7329659-B2 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1625119-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099177-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186436-A1 | SPIROCYCLIC PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NIM1K, NEK1, NEK11 | OPRK1 5/4885MAPK1 183/4885KMT2A 2555/4885 |
| US-20140256715-A1 | Novel Oxazine Derivatives and their use in the Treatment of Disease | BACE2, BACE1, PSEN1 | OPRK1 1428/4885MAPK1 1551/4885KMT2A 3038/4885 |
| US-20250205244-A1 | METHODS OF TREATING MIGRAINE WITH MNK INHIBITORS | DMPK, NIM1K, CAMKK2 | OPRK1 26/4885MAPK1 755/4885KMT2A 358/4885 |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | DMPK, PDXK, NIM1K | OPRK1 104/4885MAPK1 176/4885KMT2A 1051/4885 |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | TRPV1, ARRB1, AVPR1A | OPRK1 28/4885MAPK1 563/4885KMT2A 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.